4.6 Article

Arterial spin labeling versus BOLD in direct challenge and drug-task interaction pharmacological fMRI

Journal

PEERJ
Volume 2, Issue -, Pages -

Publisher

PEERJ INC
DOI: 10.7717/peerj.687

Keywords

phMRI (pharmacological fMRI); Functional magnetic resonance imaging; Pulsed arterial spin labeling; Tozadenant; Statistical parametric mapping; Arterial spin labeling (ASL); BOLD; Parkinson disease

Funding

  1. Synosia Therapeutics
  2. National Institutes of Health (NIH) [C06 RR020092, UL1 RR024992, P30 NS048056, U54 CA136398-02900209]
  3. American Parkinson Disease Association (APDA) Advanced Research Center for Parkinson Disease at Washington University
  4. Greater St. Louis Chapter of the APDA
  5. NIH [K24 MH087913, T32 DA007261]

Ask authors/readers for more resources

A carefully controlled study allowed us to compare the sensitivity of ASL (arterial spin labeling) and BOLD (blood oxygen level dependent) fMRI for detecting the effects of the adenosine A2a antagonist tozadenant in Parkinson disease. The study compared the effect of drug directly or the interaction of the drug with a cognitive task. Only ASL detected the direct effect of tozadenant. BOLD was more sensitive to the cognitive task, which (unlike most drugs) allows on-off comparisons over short periods of time. Neither ASL nor BOLD could detect a cognitive-pharmacological interaction. These results are consistent with the known relative advantages of each fMRI method, and suggest that for drug development, directly imaging pharmacodynamic effects with ASL may have advantages over cognitive-pharmacological interaction BOLD, which has hitherto been the more common approach to pharmacological fMRI.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available